Subcutaneous nemolizumab improves itching in atopic dermatitis patients: NEJM
Japan: Subcutaneous nemolizumab plus topical agents versus placebo plus topical agents helps in a greater reduction of itching in patients with atopic dermatitis (AD), suggests a recent study published in the New England Journal of Medicine.
Nemolizumab is a humanized monoclonal antibody against interleukin-31 receptor A which is administered subcutaneously. Interleukin-31 receptor A is involved in inflammation and pruritus (itching). Nemolizumab was shown to lessen the severity of AD in phase 2 studies but has not been well studied in patients who are also using topical agents.
Kenji Kabashima, the department of dermatology at Kyoto University, Japan, and colleagues conducted a 16-week, double-blind, phase 3 trial. Japanese patients with atopic dermatitis and moderate-to-severe pruritus and an inadequate response to topical agents were randomly assigned in a ratio of 2:1 to receive subcutaneous nemolizumab (60 mg) (n=143) or placebo (n=72) every 4 weeks until week 16, with concomitant topical agents.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.